Thus, it is hypothesised that mTOR activation upregulates SREBP activity, which in turn promotes FADS2 overexpression, contributing to ferroptosis resistance in bladder cancer cells and facilitating cancer progression. Here, MTOR is linked to urinary bladder carcinoma.